Drugs / Daratumumab-hyaluronidase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06142396 | Nov 2024 → Nov 2027 expected | kidney failure, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07085728 | Aug 2025 → Feb 2027 expected | plasma cell myeloma | Eastern Cooperative Oncology Group | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab-hyaluronidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085728 ↗ |